Not provided
Not provided
Not provided
Not provided
Not provided
enrollment constraints
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A prospective randomized, and controlled study to compare the effectiveness of PROKERA® SLIM plus standard of care (SOC) in the PROKERA® SLIM Arm to SOC alone in the Control Arm. Subjects presenting with moderate DED defined as corneal fluorescein staining score of ≥ 3 points out of 9 will be recruited.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Treatment Arm | Experimental | PROKERA SLIM + Standard of Care |
|
| Control Arm | Active Comparator | Standard of Care |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Self retained cryopreserved amniotic membrane | Device | PROKERA SLIM |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Corneal Fluorescein Staining | corneal fluorescein staining score of study eye graded from 0 to 9, with a score of 9 being worse. The corneal fluorescein staining score is the sum of three scores by subdividing the entire cornea into upper 1/3, middle 1/3, and lower 1/3, of which each is graded from 0 (no staining) to 3 (diffuse staining). | 1 month |
| Measure | Description | Time Frame |
|---|---|---|
| Eye Dryness Score | Patient subjectively evaluates eye dryness score using a visual analog scale from 0 to 100 maximal discomfort | 1 month |
| Ocular Surface Disease Index (OSDI) | Patient subjectively evaluates OSDI questionnaire, OSDI is scored on a scale of 0 to 100, with higher scores representing greater disability |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Center of Excellence in Eye Care | Miami | Florida | 33176 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Treatment Arm | PROKERA SLIM + Standard of Care PROKERA SLIM is a self retained cryopreserved amniotic membrane that is inserted once for 5 ±1 days |
| FG001 | Control Arm | Standard of Care lifitegrast ophthalmic solution: Xiidra® (5% lifitegrast ophthalmic solution, Shire, Lexington, MA) |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Treatment Arm | PROKERA SLIM + Standard of Care Self retained cryopreserved amniotic membrane: PROKERA SLIM lifitegrast ophthalmic solution: Xiidra® (5% lifitegrast ophthalmic solution, Shire, Lexington, MA) |
| BG001 | Control Arm |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Corneal Fluorescein Staining | corneal fluorescein staining score of study eye graded from 0 to 9, with a score of 9 being worse. The corneal fluorescein staining score is the sum of three scores by subdividing the entire cornea into upper 1/3, middle 1/3, and lower 1/3, of which each is graded from 0 (no staining) to 3 (diffuse staining). | Posted | Mean | Standard Deviation | units on a scale | 1 month |
|
3 months
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Treatment Arm | PROKERA SLIM + Standard of Care Self retained cryopreserved amniotic membrane: PROKERA SLIM lifitegrast ophthalmic solution: Xiidra® (5% lifitegrast ophthalmic solution, Shire, Lexington, MA) |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Medical Affairs | BioTissue | 8882968858 | medicalaffairs@biotissue.com |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Apr 5, 2019 | Oct 18, 2022 | Prot_SAP_000.pdf |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D015352 | Dry Eye Syndromes |
| ID | Term |
|---|---|
| D007766 | Lacrimal Apparatus Diseases |
| D005128 | Eye Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C575157 | lifitegrast |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| lifitegrast ophthalmic solution |
| Other |
Xiidra® (5% lifitegrast ophthalmic solution, Shire, Lexington, MA) |
|
|
| 1 month |
Standard of Care
lifitegrast ophthalmic solution: Xiidra® (5% lifitegrast ophthalmic solution, Shire, Lexington, MA)
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Count of Participants | Participants |
|
|
|
| Secondary | Eye Dryness Score | Patient subjectively evaluates eye dryness score using a visual analog scale from 0 to 100 maximal discomfort | Posted | Mean | Standard Deviation | units on a scale | 1 month |
|
|
|
| Secondary | Ocular Surface Disease Index (OSDI) | Patient subjectively evaluates OSDI questionnaire, OSDI is scored on a scale of 0 to 100, with higher scores representing greater disability | Posted | Mean | Standard Deviation | units on a scale | 1 month |
|
|
|
| 0 |
| 2 |
| 0 |
| 2 |
| 0 |
| 2 |
| EG001 | Control Arm | Standard of Care lifitegrast ophthalmic solution: Xiidra® (5% lifitegrast ophthalmic solution, Shire, Lexington, MA) | 0 | 1 | 0 | 1 | 0 | 1 |
Not provided
Not provided